COCRYSTALLINE DHEA FORMULATIONS

Anders L. Berkenstam; Edward Kuczynski,; S Andersson, Alf; Jan-Ake Gustafsson,; Carly S. Filgueira

COCRYSTALLINE DHEA FORMULATIONS

Anders L. Berkenstam (Inventor), Edward Kuczynski, (Inventor), S Andersson, Alf (Inventor), Jan-Ake Gustafsson, (Inventor), Carly S. Filgueira (Inventor)

Research output: Patent

Abstract

A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

Original language	English (US)
Patent number	WO2014172706
IPC	A61K 38/ 22 A I
Priority date	4/19/13
State	Published - Oct 23 2014

Cite this

@misc{32c55ad531df4e96b178091db42cb358,

title = "COCRYSTALLINE DHEA FORMULATIONS",

abstract = "A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.",

author = "Berkenstam, \{Anders L.\} and Edward Kuczynski, and \{Andersson, Alf\}, S and Jan-Ake Gustafsson, and Filgueira, \{Carly S.\}",

year = "2014",

month = oct,

day = "23",

language = "English (US)",

type = "Patent",

note = "WO2014172706; A61K 38/ 22 A I",

}

TY - PAT

T1 - COCRYSTALLINE DHEA FORMULATIONS

AU - Berkenstam, Anders L.

AU - Kuczynski,, Edward

AU - Andersson, Alf, S

AU - Gustafsson,, Jan-Ake

AU - Filgueira, Carly S.

PY - 2014/10/23

Y1 - 2014/10/23

N2 - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

AB - A cocrystalline DHEA composition with at least one additional coformer is disclosed for therapeutic formulations. The cocrystalline DHEA/coformer formulation including at least one coformer chosen from the group consisting of glutaric acid, maleic acid, tartaric acid, fructose, and wherein the L-isomer of tartaric acid and the D-isomer of fructose are utilized. The cocrystalline DHEA/coformer formulations include certain excipients as a solubilizer or inhibitor.

M3 - Patent

M1 - WO2014172706

ER -

COCRYSTALLINE DHEA FORMULATIONS

Abstract

Fingerprint

Cite this